期刊文献+

Coffee protection against the development of hepatocellular carcinoma: review article

原文传递
导出
摘要 Coffee, a popular drink around the world, is composed of a complex mix of biologically active molecules, including caffeine, chlorogenic acid, and diterpenes. These compounds have antioxidant, anti-inflammatory, antifibrotic, and anticarcinogenic properties, which may explain observational data showing that coffee drinkers have lower rates of chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). Recent studies have also shown that coffee consumption may also increase patient survival before and after liver transplantation. The mechanism by which coffee consumption protects against HCC is not clear;however, its relevant role has been demonstrated. This literature review article focuses on the role of coffee consumption in protecting against the development of HCC. Methodology: Scientific articles indexed through PubMed, including Medline, Scielo, and Lilacs, published in English were used as search methods. The terms used in English were: "hepatocellular carcinoma" or "Liver cancer" or "HCC" and "coffee". According to the study design or review article, cross-sectional, longitudinal, or descriptive investigations were included, showing site and year of publication until 2019.
出处 《Hepatoma Research》 2020年第2期33-38,共6页 肝癌研究(英文版)
  • 相关文献

参考文献1

二级参考文献132

  • 1Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanismsin HBV- and HCV-associated hepatocellular carcinoma. Nat RevCancer 2013; 13: 123-135 [PMID: 23344543 DOI: 10.1038/nrc3449].
  • 2Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, MaadIB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B,Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, CalvoF, Zucman-Rossi J. Integrated analysis of somatic mutations andfocal copy-number changes identifies key genes and pathways inhepatocellular carcinoma. Nat Genet 2012; 44: 694-698 [PMID:22561517 DOI: 10.1038/ng.2256].
  • 3Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G,Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H. Alterationsof RB1, p53 and Wnt pathways in hepatocellular carcinomasassociated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.Int J Cancer 2003; 106: 334-341 [PMID: 12845670 DOI: 10.1002/ijc.11254].
  • 4Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, Zhao X, Zhang H,Liu S, Zhong Y, Zou Z, Zhao Y, Yu K, He L, Sang X, Zhong S,Huang J, Wu Y, Miksad RA, Robson SC, Jiang C, Zhao Y, Zhao H.Identification of prognostic biomarkers in hepatitis B virus-relatedhepatocellular carcinoma and stratification by integrative multiomicsanalysis. J Hepatol 2014; 61: 840-849 [PMID: 24859455DOI: 10.1016/j.jhep.2014.05.025].
  • 5Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M,Shimazaki J, Yoshimi F, Fukao K. Expression and prognostic rolesof beta-catenin in hepatocellular carcinoma: correlation with tumorprogression and postoperative survival. Clin Cancer Res 2002; 8:450-456 [PMID: 11839663].
  • 6Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, BaekD, Haq F, Ansari AA, Lee SY, Chun SM, Choi S, Choi HJ, KimJ, Kim S, Hwang S, Lee YJ, Lee JE, Jung WR, Jang HY, YangE, Sung WK, Lee NP, Mao M, Lee C, Zucman-Rossi J, Yu E,Lee HC, Kong G. Genomic portrait of resectable hepatocellularcarcinomas: implications of RB1 and FGF19 aberrations for patientstratification. Hepatology 2014; 60: 1972-1982 [PMID: 24798001DOI: 10.1002/hep.27198].
  • 7Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpGisland hypermethylation along multistep hepatocarcinogenesis. AmJ Pathol 2003; 163: 1371-1378 [PMID: 14507645 DOI: 10.1016/S0002-9440(10)63495-5].
  • 8Okamoto Y, Shinjo K, Shimizu Y, Sano T, Yamao K, Gao W,Fujii M, Osada H, Sekido Y, Murakami S, Tanaka Y, Joh T, SatoS, Takahashi S, Wakita T, Zhu J, Issa JP, Kondo Y. Hepatitis virusinfection affects DNA methylation in mice with humanized livers.Gastroenterology 2014; 146: 562-572 [PMID: 24184133 DOI:10.1053/j.gastro.2013.10.056].
  • 9Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N,Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M,Watahiki S, Mineta R, Kumada H. Long-term continuous entecavirtherapy in nucleos(t)ide-na-ve chronic hepatitis B patients. JHepatol 2012; 57: 508-514 [PMID: 22659518 DOI: 10.1016/j.jhep.2012.04.037].
  • 10Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P,Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S,Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.Simeprevir with peginterferon and ribavirin leads to high rates ofSVR in patients with HCV genotype 1 who relapsed after previoustherapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-1679.e3[PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051].

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部